Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Atara Biotherap
(NQ:
ATRA
)
7.140
+0.020 (+0.28%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Atara Biotherap
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Read Why Did HC Wainwright Cut Price Target On Atara Biotherapeutics
May 23, 2022
Via
Benzinga
HC Wainwright & Co. Maintains Buy Rating for Atara Biotherapeutics: Here's What You Need To Know
May 23, 2022
HC Wainwright & Co. has decided to maintain its Buy rating of Atara Biotherapeutics (NASDAQ:ATRA) and lower its price target from $31.00 to $29.00. Shares of Atara Biotherapeutics are trading down 3.1%...
Via
Benzinga
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
May 20, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
May 20, 2022
Via
Benzinga
Earnings Scheduled For February 28, 2022
February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...
Via
Benzinga
Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
May 20, 2022
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
May 19, 2022
Gainers Radius Health (NASDAQ:RDUS) stock moved upwards by 18.8% to $6.94 during Thursday's after-market session. The company's market cap stands at $330.1 million.
Via
Benzinga
Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer
May 19, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 06, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022
May 10, 2022
Upgrades
Via
Benzinga
Atara Biotherapeutics Announces First Quarter 2022 Financial Results and Operational Progress
May 05, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Earnings Preview
May 04, 2022
Atara Biotherapeutics (NASDAQ:ATRA) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Atara...
Via
Benzinga
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 29, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Announce First Quarter 2022 Financial Results on Thursday, May 5, 2022
April 28, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 22, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 08, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Names Biopharmaceutical Executive Charlene Banard as Chief Technical Officer
April 05, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
April 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Atara Biotherapeutics Announces the Completion of the Acquisition of Its Cell Therapy Manufacturing Facility & Commencement of Long-Term Strategic Partnership with Fujifilm
April 04, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Host EBV and MS Day
March 15, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
March 01, 2022
Gainers Avenue Therapeutics (NASDAQ:ATXI) shares rose 172.1% to $0.92 during Tuesday's regular session. As of 12:30 EST, this security is trading at a volume of 157.8...
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
March 02, 2022
Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by...
Via
Benzinga
80 Biggest Movers From Yesterday
March 02, 2022
Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) jumped 78.5% to close at $0.6066 on Tuesday after jumping 36% on Monday. CTI BioPharma Corp. (NASDAQ: CTIC) surged 63...
Via
Benzinga
44 Stocks Moving In Tuesday's Mid-Day Session
March 01, 2022
Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) climbed 193% to $0.9962 after jumping 36% on Monday. GBS Inc. (NASDAQ: GBS) rose 73.3% to $0.7971 after declining around 9% on...
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
March 01, 2022
During Tuesday's trading, 98 companies set new 52-week lows. Intriguing Points From Today's 52-Week Lows And Highs: JPMorgan Chase (NYSE:JPM) was the...
Via
Benzinga
Preview: Atara Biotherapeutics's Earnings
February 25, 2022
Atara Biotherapeutics (NASDAQ:ATRA) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
Psychedelic Drugs Market Growing as Prevalence of Mental Health Issues are Increasing Globally
February 24, 2022
Palm Beach, FL –– February 24, 2022 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially but the development of novel medications has not kept...
Via
FinancialNewsMedia
Exposures
COVID-19
Atara Biotherapeutics Shares Fall After Reporting Patient Death In ATA2271 Autologous CAR T Trial
February 18, 2022
Memorial Sloan Kettering Cancer Center's (MSK) has notified the FDA of a fatal serious adverse event (SAE) associated with a patient in Phase 1 study of Atara...
Via
Benzinga
Atara Biotherapeutics Provides Update on ATA2271 Autologous CAR T Trial
February 18, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022
February 17, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.